Citius Pharmaceuticals, Inc. (CTXR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Pharmaceuticals, Inc. on February 6, 2025. The company, incorporated in Nevada and trading on the Nasdaq Capital Market, operates with an oncology-focused subsidiary, Citius Oncology, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a regulatory milestone.
Material Changes
On February 6, 2025, the Centers for Medicare & Medicaid Services (CMS) assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code to the company's product LYMPHIR™ (denileukin diftitox-cxdl). This event is reported under Item 8.01 Other Events.
Guidance, Outlook, and Management Commentary
The filing incorporates a press release (Exhibit 99.1) regarding the J-code assignment. No specific financial guidance, future outlook, risk factors, or management commentary beyond the announcement of the coding assignment is provided in this document.
Investor Verification Checklist
- Verify the specific J-code assigned to LYMPHIR™ in the attached press release (Exhibit 99.1).
- Confirm the effective date for reimbursement eligibility associated with the new J-code.
- Review the company's most recent 10-K or 10-Q for current financial health and cash runway, as this 8-K contains no financial data.
- Assess the potential commercial impact of permanent J-code assignment on the product's market access and revenue projections.